Recent Quotes (30 days)

You have no recent quotes
chg | %

Takeda Pharmaceutical Co Ltd news

   Watch this stock
Showing stories 1 - 10 of about 121   

Articles published

4502 5,903.00 +43.00 (0.73%)
price chart
Takeda, Lilly Jury Awards $9 Billion Over Actos Risks
Takeda Pharmaceutical Co. (4502) and Eli Lilly & Co. (LLY) were ordered to pay a combined $9 billion in punitive damages after a federal court jury found they hid the cancer risks of their Actos diabetes medicine in the first U.S.
Takeda Pharmaceutical Co.'s share price down, sentenced to pay 6 billion ...  Binary Tribune
Japan drugmaker Takeda to fight $6 billion damages awarded by US jury  Reuters
Related articles »  
Takeda, Lilly lose bid to overturn $9 billion award for hiding cancer risk
Lilly, which co-promoted Actos from 1999 to 2006, was not immediately available to comment. The company has previously said it will be indemnified by Takeda for its losses and expenses from the litigation based on the terms of its agreement with Takeda.
Takeda Announces Completion of the Post-Marketing Commitment to Submit ...  MarketWatch
Takeda, Lilly Lose Bid to Overturn $9 Billion Actos Award  Businessweek
Related articles »  
Takeda Presents Additional Data from the EXAMINE Cardiovascular Safety ...
WASHINGTON and OSAKA, Japan, March 27, 2014 /CNW/ - Takeda Pharmaceutical Company Limited (Takeda) will present sub-analyses from the global EXAMINE (EXamination of CArdiovascular OutcoMes: AlogliptIN vs.
Related articles »  
Wipro bags Rs 2400 crore Takeda Pharma deal
BANGALORE: Wipro has won an over $400 million (Rs 2,400 crore) deal from Takeda Pharma under which the former will develop and support IT requirements of the largest Japanese pharmaceutical company. The multi-year deal, described as a "strategic ...
Takeda Pharmaceuticals Partners with Wipro to Enable a Global "as-a ...  MarketWatch
Wipro bags IT contract from Japan's Takeda Pharmaceuticals  Business Standard
Related articles »  
BioMotiv and Takeda Pharmaceutical Company Enter into Strategic Partnership
CLEVELAND & OSAKA, Japan, Sep 25, 2014 (BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (�Takeda�) and BioMotiv, LLC, the therapeutic accelerator company associated with The Harrington Project for Discovery & Development, jointly ...
Related articles »  
Narrower of Possible Claim Constructions Prevails - Takeda Pharmaceutical Co ...
Takeda Pharmaceutical Co. Ltd. v. Zydus Pharma USA, Inc., Case No. 13-1406 (Fed. Cir., Feb. 20, 2014) (Prost, J.). Takeda Pharmaceutical and several related entities own patents claiming the formulation for the brand-name drug Prevacid� SolutabTM, ...
Takeda's ixazomib a Breakthrough Therapy for amyloidosis
The FDA designates Takeda Pharmaceutical Company's (OTCPK:TKPHF) (OTCPK:TKPYY) investigational oral proteasome inhibitor, ixazomib, a Breakthrough Therapy for the treatment of relapsed or refractory systemic light-chain (AL) amyloidosis.
Takeda's Investigational, Oral Proteasome Inhibitor Ixazomib Granted ...  Business Wire India (press release)
Takeda: FDA Grants Breakthrough Therapy Status To Ixazomib  Nasdaq
Related articles »  
Takeda Pharmaceutical to stay Japan-based while growing on global basis, new ...
The inauguration in June of Christophe Weber as president of Takeda Pharmaceutical Co. invited opposition from a group of its former executives and members of its founding family, but the Frenchman says Takeda will remain �Japanese-based� under his ...
Related articles »  
Stocks Buzz- Civeo Corp(CVEO), Takeda Pharmaceutical Co Ltd (ADR)(TKPYY ...
Houston, TX - Jan 10, 2015 - (Techsonian) - Civeo Corp(NYSE:CVEO) declared the company's initial 2015 guidance, which reflects decisions by major oil companies in North America to considerably reduce 2015 capital spending, particularly in Canada, ...
Takeda Pharmaceutical (TKPHF) Q2 2014 Results - Earnings Call Transcript ...
Thank you very much for your participation in the conference call of the First Quarter Financial Results for Fiscal Year 2014 of Takeda Pharmaceutical Company Limited. My name is Christopher Hohman, Senior Vice President of the Corporate ...